Login to Your Account



Clinic Roundup


Friday, November 11, 2011
• BioDelivery Sciences International Inc., of Raleigh, N.C., said it started a confirmatory study of a formulation of buprenorphine and naloxone using BDSI's BioErodible MucoAdhesive drug delivery technology. The study will be used to select the final doses of BEMA Buprenorphine/Nalaxone to be used in the pivotal bioequivalence study compared to Suboxone set to start in January 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription